0
Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

Letters   |    
Successful Treatment With Blonanserin for Drug-Induced Hyperprolactinemia in Chronic Schizophrenia Patients: A Six-Month Follow-Up of Two Cases
Shinsuke Kito, M.D., Ph.D.; Takashi Hasegawa, M.D., Ph.D.; Toru Nakajima, M.D., Ph.D.; Yoshihiko Koga, M.D., Ph.D.; Shintaro Hibi, M.D.; Yukiko Tobe, M.D.; Masahiko Mochida, M.D., Ph.D.
The Journal of Neuropsychiatry and Clinical Neurosciences 2013;25:E29-E30. doi:10.1176/appi.neuropsych.12060161
View Author and Article Information

Dept. of Neuropsychiatry Kyorin University School of Medicine Tokyo, Japan
Tokyokaido Hospital Tokyo, Japan
Tama Hospital Tokyo, Japan

Correspondence: Shinsuke Kito, M.D., Ph.D.; e-mail: kito@ks.kyorin-u.ac.jp

Copyright © 2013 American Psychiatric Association

Extract

To the Editor: Some antipsychotics cause elevations in serum prolactin (PRL) levels, which can lead to galactorrhea, infertility, menstrual disorders, sexual dysfunction, and reduction in bone mineral density,1 although recent atypical antipsychotics do so less often than conventional ones. We present two cases of chronic schizophrenia with risperidone-induced hyperprolactinemia, of whom one, especially, had sexual dysfunction. Their elevated PRL levels were normalized after switching to blonanserin.

Figures in this Article

First Page Preview

View Large
/>
First page PDF preview
Your Session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Anchor for Jump
TABLE 1.Clinical Characteristics and Changes in Serum PRL Levels in Two Schizophrenia Patients With a Six-Month Follow-Up
Table Footer Note

BW indicates body weight (kg); PRL, prolactin (ng/ml); BPRS, Brief Psychiatric Rating Scale score.

+

References

Haddad  PM;  Wieck  A:  Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.  Drugs 2004; 64:2291–2314
[CrossRef] | [PubMed]
 
Deeks  ED;  Keating  GM:  Blonanserin: a review of its use in the management of schizophrenia.  CNS Drugs 2010; 24:65–84
[CrossRef] | [PubMed]
 
Kapur  S;  Langlois  X;  Vinken  P  et al:  The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood–brain disposition: a pharmacological analysis in rats.  J Pharmacol Exp Ther 2002; 302:1129–1134
[CrossRef] | [PubMed]
 
Arakawa  R;  Okumura  M;  Ito  H  et al:  Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.  J Clin Psychiatry 2010; 71:1131–1137
[CrossRef] | [PubMed]
 
Inoue  T;  Osada  K;  Tagawa  M  et al:  Blonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoprotein.  Prog Neuropsychopharmacol Biol Psychiatry 2012; 39:156–162[E-pub ahead of print]
[CrossRef] | [PubMed]
 
References Container
+
+

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content
Books
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 26.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 20.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 20.  >
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 55.  >
The American Psychiatric Publishing Textbook of Geriatric Psychiatry, 4th Edition > Chapter 26.  >
Topic Collections
Psychiatric News
Read more at Psychiatric News >>
APA Guidelines